Acadian Asset Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Acadian Asset Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-732,669	Closed	-$2.37M	–	2271
2021 Q1	$2.37M	Sell	732,669 -61,917	-8%	-$207K	0.01%	692
2020 Q4	$1.68M	Buy	794,586 +147,192	+23%	+$243K	0.01%	813
2020 Q3	$758K	Buy	647,394 +51,482	+9%	+$52.9K	﹤0.01%	1006
2020 Q2	$539K	Buy	595,912 +7,038	+1%	+$6.71K	﹤0.01%	1166
2020 Q1	$493K	Sell	588,874 -44,736	-7%	-$51.9K	﹤0.01%	963
2019 Q4	$609K	Buy	633,610 +12,765	+2%	+$14K	﹤0.01%	1028
2019 Q3	$640K	Buy	620,845 +19,328	+3%	+$26.3K	﹤0.01%	1015
2019 Q2	$1.08M	Buy	601,517 +58,998	+11%	+$95K	0.01%	786
2019 Q1	$1.02M	Buy	542,519 +60,383	+13%	+$88.3K	﹤0.01%	883
2018 Q4	$569K	Buy	482,136 +127,670	+36%	+$230K	﹤0.01%	873
2018 Q3	$961K	Sell	354,466 -17,543	-5%	-$36.3K	﹤0.01%	731
2018 Q2	$711K	Buy	372,009 +181,436	+95%	+$367K	﹤0.01%	811
2018 Q1	$400K	Buy	190,573 +158,007	+485%	+$339K	﹤0.01%	915
2017 Q4	$66K	Sell	32,566 -4,418	-12%	-$9.17K	﹤0.01%	1180
2017 Q3	$49K	Sell	36,984 -155,292	-81%	-$193K	﹤0.01%	1110
2017 Q2	$301K	Sell	192,276 -392,956	-67%	-$758K	﹤0.01%	903
2017 Q1	$1.89M	Buy	585,232 +511,057	+689%	+$1.26M	0.01%	632
2016 Q4	$101K	Sell	74,175 -62,918	-46%	-$82.2K	﹤0.01%	1098
2016 Q3	$213K	Sell	137,093 -198,110	-59%	-$304K	﹤0.01%	960
2016 Q2	$446K	Buy	335,203 +23,564	+8%	+$110K	﹤0.01%	796
2016 Q1	$1.64M	Sell	311,639 -270,639	-46%	-$1.66M	0.01%	575
2015 Q4	$4.57M	Sell	582,278 -449,616	-44%	-$3.87M	0.02%	414
2015 Q3	$8.72M	Sell	1,031,894 -219,585	-18%	-$2.03M	0.05%	305
2015 Q2	$13.7M	Buy	1,251,479 +475,747	+61%	+$6.11M	0.07%	241
2015 Q1	$10.8M	Buy	775,732 +558,718	+257%	+$8.54M	0.05%	273
2014 Q4	$3.67M	Buy	+217,014	New	+$3.16M	0.02%	450

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GPC

Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Acadian Asset Management's INFI Position: Q2 2021 in Review

Acadian Asset Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2021, closing a stake of 732,669 shares — an estimated $2.37M sold.

Acadian Asset Management first reported a position in INFI in Q4 2014 and held it in 26 quarters. The position peaked at $13.7M in Q2 2015. 97 funds tracked by Wall St. Rank hold INFI as of Q2 2021.

Acadian Asset Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Acadian Asset Management sold 732,669 Infinity Pharmaceuticals, Inc. shares in Q2 2021, an estimated $2.37M.
Acadian Asset Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 26 quarters.
Acadian Asset Management's Infinity Pharmaceuticals, Inc. position peaked at $13.7M in Q2 2015.
97 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2021.

Based on Acadian Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.